Fresenius SE & Co KGaA (FRE) PT Set at €46.00 by UBS Group

Fresenius SE & Co KGaA (FRA:FRE) received a €46.00 ($53.49) price target from equities researchers at UBS Group in a report issued on Monday, www.boersen-zeitung.de reports. The brokerage currently has a “neutral” rating on the stock. UBS Group’s target price indicates a potential downside of 2.54% from the company’s current price.

FRE has been the subject of a number of other research reports. Barclays set a €80.00 ($93.02) price objective on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Tuesday, October 30th. Sanford C. Bernstein set a €76.50 ($88.95) price objective on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Friday, December 7th. Deutsche Bank set a €75.00 ($87.21) price objective on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Monday, November 26th. Oddo Bhf set a €50.00 ($58.14) price objective on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Monday, December 10th. Finally, Independent Research set a €66.00 ($76.74) price target on shares of Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a report on Wednesday, October 17th. Nine analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of €61.55 ($71.57).

FRA FRE opened at €47.20 ($54.88) on Monday. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($69.95) and a 12-month high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Story: How to read a candlestick chart

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply